Associate Professor Ng Kok Pin is a Senior Consultant Neurologist at the Department of Neurology, National Neuroscience Institute, Singapore, and the Service Chief, NNI@TTSH for the SingHealth Duke-NUS Memory and Cognitive Disorder Centre. Assoc Prof Ng is the Assistant Director, Research (Research Program) of NNI and Executive Committee Member of the SingHealth AI Office. His research work focuses on the cognitive and behavioral aspects of neurocognitive diseases using platforms such as biomarkers, neuroimaging and MedTech.

Assoc Prof Ng holds academic appointments at the Duke-NUS Medical School, Singapore, Yong Loo Lin School of Medicine, Singapore and Lee Kong Chian School of Medicine, Singapore. He is also a Board Member for the Chapter of Neurologists, Academy of Medicine, Singapore. 

• MCI (NUS), 2015
• MRCP (UK), 2011
• MBBS National University of Singapore, 2006

• Senior Consultant, Department of Neurology, National Neuroscience Institute
• Clinical Associate Professor – DUKE-NUS Medical School, Singapore
• Adjunct Assistant Professor – Lee Kong Chian School of Medicine, Singapore
• Clinical Lecturer – Yong Loo Lin School of Medicine, Singapore
• Executive Committee Member of SingHealth AI Office
• Service Chief @ NNI TTSH Campus - SingHealth Duke-NUS Memory and Cognitive Disorder Centre
• Board Member, Chapter of Neurologists, Academy of Medicine, Singapore

• SingHealth GCEO Outstanding Researcher Award - 2025
• Singapore Health Quality Service Award, Star - 2024
• Singapore Health Quality Service Award, Gold - 2023
• NMRC Research Training Fellowship Award - 2021 

• Wilbur Zhi Hao Koh, See Ann Soo, Seyed Ehsan Saffari, Hui Jin Chiew, Adeline Su Lyn Ng, K.P. Ng*, Kandiah, N.*, 2024. Normative data for baseline and longitudinal neuropsychological assessments in Singapore,  Ann Acad Med Singap. 2024 Jan 30;53(1):48-52. *Joint Last Authors
• Ng, K.P.*, Shen, J.Y.*, Chiew, H.J., Ng, A.S.L., Kandiah, N., Rosa-Neto, P. and Gauthier, S., 2023. White Matter Hyperintensity as a Vascular Contribution to the AT (N) Framework. The Journal of Prevention of Alzheimer's Disease, pp.1-14. *contributed equally
• Ng, K.P.*, Qian, X.*, Ng, K.K., Ji, F., Rosa-Neto, P., Gauthier, S., Kandiah, N., Zhou, J.H. and Alzheimer's Disease Neuroimaging Initiative, 2022. Stage-dependent differential influence of metabolic and structural networks on memory across Alzheimer’s disease continuum. Elife, 11, p.e77745. *contributed equally
• Ng, K.P.*, Chiew, H.J.*, Rosa-Neto, P., Kandiah, N., Ismail, Z. and Gauthier, S., 2021. Associations of AT (N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals. Translational neurodegeneration, 10(1), pp.1-14 *contributed equally
• Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Chan, Y.H., Jiang, L., Therriault, J., Benedet, A.L., Shin, M., Kandiah, N., Greenwood, C.M. and Rosa-Neto, P., 2021. Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease. Translational Neurodegeneration, 10(1), pp.1-11. ​
• Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., et al. 2017. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology, 88(19), pp.1814-1821.
• Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Therriault, J., Kang, M.S., Shin, M., Guiot, M.C., Guo, Q., Harada, R., Comley, R.A. and Massarweh, G., 2017. Monoamine oxidase B inhibitor, selegiline, reduces 18 F-THK5351 uptake in the human brain. Alzheimer's Research & Therapy, 9(1), p.25.
• Li, X., Ba, M., Ng, K.P., Mathotaarachchi, S., Pascoal, T.A., Rosa-Neto, P., Gauthier, S. and Alzheimer's Disease Neuroimaging Initiative, 2017. Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.
• Ng, K.P., Ng, A., Assam, P., Heng, E. and Kandiah, N., 2014. Role of cognitive enhancer therapy in Alzheimer’s disease with concomitant cerebral white matter disease: findings from a long-term naturalistic study. Drugs in R&d, 14(3), pp.195-203.
• Ba, M., Li, X., Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., Rosa-Neto, P., Gauthier, S. and Alzheimer's Disease Neuroimaging Initiative, 2017. The prevalence and biomarkers’ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 3(1), pp.107-113.
• Ba, M., Kong, M., Li, X., Ng, K.P., Rosa-Neto, P. and Gauthier, S., 2016. Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer’s disease?. Translational Neurodegeneration, 5(1), p.20.